Eczacıbaşı Health Products

Eczacıbaşı Pharmaceuticals is a leading Turkish healthcare company and a core division of the Eczacıbaşı Group, a major industrial conglomerate founded in 1942. The company operates as a vertically integrated player in the pharmaceutical sector, following its 2022 acquisition of Gensenta, which restored its large-scale manufacturing capabilities for active pharmaceutical ingredients (APIs) and finished dosage forms. Eczacıbaşı manages a diverse portfolio through its marketing and distribution arm, Eczacıbaşı Pharmaceuticals Marketing, which maintains strategic partnerships with global leaders such as Novartis and Pharma Mar. The company has a strong presence in therapeutic areas including oncology, hematology, and the central nervous system, and was a pioneer in the radiopharmaceutical space through its long-term joint venture, Eczacıbaşı-Monrol. With a focus on both innovative and generic medicines, Eczacıbaşı continues to be a dominant force in the Turkish healthcare market while expanding its export footprint globally.